ARTICLE | Company News
FDA approves Aimovig as first CGRP inhibitor for migraines
May 18, 2018 4:05 AM UTC
FDA approved Aimovig erenumab from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) late Thursday to prevent migraine in adults. The drug is the first calcitonin gene-related peptide (CGRP) inhibitor approved for the indication.
Amgen said it expects to launch Aimovig within a week at an annual wholesale acquisition cost (WAC) of $6,900...
BCIQ Target Profiles